-

Natera to Report its First Quarter 2024 Results on May 9

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2024, after the market close on May 9, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).

Earnings Conference Call Information:

Event:

Natera’s First Quarter 2024 Financial Results

Date:

Thursday, May 9, 2024

Time:

1:30 p.m. PT (4:30 p.m. ET)

Live Dial-In:

1 (888) 770-7321 (Domestic)

 

1 (929) 201-7107 (International)

Conference ID:

7684785

Webcast:

https://events.q4inc.com/attendee/575350879

A webcast replay will be available at investor.natera.com.

About Natera

Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 200 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-405-4709, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

Industry:

Natera, Inc.

NASDAQ:NTRA
Release Versions
English

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-405-4709, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

More News From Natera, Inc.

Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, Jan. 13, 2026 at 4:30 p.m. PT (7:30 p.m. ET). Members of management will deliver a presentation and host a Q&A with the investment community at the conference. A live webcast may be accessed through the investor relations section of the Natera websit...

Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in JAMA Oncology. This publication builds on the initial presentation of results at the 2025 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI) earlier this year. CALGB (Alliance)/SWOG 80702 assessed the predictive value of postoperative...

I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Quantum Leap Healthcare Collaborative, today announced the publication of new findings from the I-SPY 2 trial in Nature Communications. The study examined how Signatera can refine risk assessment in patients with early-stage breast cancer whose tumors resist neoadjuvant therapy (NAT). These cancers often leave behind substantial residual disease and carry a higher...
Back to Newsroom